STOCK TITAN

Revance Therapeu Stock Price, News & Analysis

RVNC NASDAQ

Company Description

Overview of Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a specialty biotechnology company focused on the development, manufacturing, and commercialization of innovative botulinum toxin products for aesthetic and therapeutic indications. Leveraging cutting-edge technologies in biotechnology and medical aesthetics, Revance is redefining traditional treatment paradigms with its proprietary portfolio and patented TransMTS® peptide delivery system.

Innovative Technology and Product Offerings

The company harnesses its proprietary TransMTS® technology to offer dual formulations of botulinum toxin products, including a needle-free, topical gel and an injectable form. This novel approach enables targeted delivery of the active ingredient, potentially providing more localized and longer lasting therapeutic effects. Such innovation is particularly significant for patients interested in non-invasive aesthetic treatments and therapeutic solutions aimed at addressing a wide range of conditions.

Clinical Development and Market Position

Revance is actively engaged in clinical development for its key candidates, including a topical gel formulation and its injectable counterpart. These product candidates are designed to address unmet needs in the expansive neurotoxin market, which is a key segment within the broader aesthetics and dermatology sectors. The company's robust research and development framework, combined with extensive clinical collaborations, underscores its role as a trendsetter in biotechnology and is highly regarded among healthcare professionals and stakeholders in medical aesthetics.

Business Model and Strategic Partnerships

Revance’s business model revolves around leveraging its proprietary technology to create differentiated product offerings. Revenue generation is primarily through clinical development milestones and eventual commercialization, supported by strategic partnerships that expand its product portfolio and market reach. The company’s alliances with key industry players enable enhanced distribution channels and provide a solid foundation for its therapeutic and aesthetic solutions.

Operational Excellence and Industry Expertise

With a focus on operational excellence, Revance has established itself as a company that meticulously negotiates regulatory requirements while driving technological innovation in drug delivery systems. Its expertise in biopharmaceutical manufacturing and its commitment to quality cements its reputation as a trusted entity in the competitive landscape of biotechnology and aesthetics. Detailed attention to clinical validation and stringent quality controls further enhances the company’s credibility and trustworthiness among its peers and the medical community.

Commitment to Innovation and Customer Value

Revance is dedicated to transforming aesthetic and therapeutic medicine by enhancing patient outcomes and physician experiences. The integration of innovative delivery mechanisms in its product formulations not only addresses long-standing challenges in medical aesthetics but also sets new standards in treatment efficacy and safety.

Conclusion

In summary, Revance Therapeutics, Inc. exemplifies innovation in the biotechnology sector with deep-rooted expertise in botulinum toxin applications. Its strategic focus on novel drug delivery methods, backed by rigorous clinical investigations and collaborative industry partnerships, positions the company as an influential, unbiased source of advanced therapeutic solutions in the global aesthetics and medical aesthetics market.

Stock Performance

$—
0.00%
0.00
Last updated:
-67.35 %
Performance 1 year
$381.0M
Market Cap
104.4M
Shares outstanding

SEC Filings

No SEC filings available for Revance Therapeu.

Financial Highlights

$59,879,000
Revenue (TTM)
-$38,115,000
Net Income (TTM)
-$0.37
Diluted EPS (TTM)
-$41,090,000
Operating Cash Flow
-63.65%
Net Profit Margin
-53.87%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Revance Therapeu (RVNC)?

The current stock price of Revance Therapeu (RVNC) is $3.65 as of February 7, 2025.

What is the market cap of Revance Therapeu (RVNC)?

The market cap of Revance Therapeu (RVNC) is approximately 381.0M.

What is the revenue (TTM) of Revance Therapeu (RVNC) stock?

The trailing twelve months (TTM) revenue of Revance Therapeu (RVNC) is $59,879,000.

What is the net income of Revance Therapeu (RVNC)?

The trailing twelve months (TTM) net income of Revance Therapeu (RVNC) is -$38,115,000.

What is the earnings per share (EPS) of Revance Therapeu (RVNC)?

The diluted earnings per share (EPS) of Revance Therapeu (RVNC) is -$0.37 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Revance Therapeu (RVNC)?

The operating cash flow of Revance Therapeu (RVNC) is -$41,090,000.

What is the profit margin of Revance Therapeu (RVNC)?

The net profit margin of Revance Therapeu (RVNC) is -63.65%.

What is the operating margin of Revance Therapeu (RVNC)?

The operating profit margin of Revance Therapeu (RVNC) is -53.87%.

What is the current ratio of Revance Therapeu (RVNC)?

The current ratio of Revance Therapeu (RVNC) is 4.12, indicating the company's ability to pay short-term obligations.

What is the operating income of Revance Therapeu (RVNC)?

The operating income of Revance Therapeu (RVNC) is -$32,256,000.

What is the core focus of Revance Therapeutics, Inc.?

Revance Therapeutics is a biotechnology company that develops, manufactures, and commercializes novel botulinum toxin products for both aesthetic and therapeutic indications, leveraging advanced delivery technologies.

How does Revance differentiate its product offerings?

The company utilizes its proprietary TransMTS® peptide delivery system to provide both needle-free topical and injectable formulations, enabling targeted and potentially longer lasting therapeutic effects.

What market segments does Revance serve?

Revance operates within the biotechnology and aesthetics markets, specifically addressing both the aesthetic and therapeutic segments with innovative neurotoxin treatments.

How does Revance generate revenue?

Revenue is primarily generated through clinical development milestones and the eventual commercialization of its unique botulinum toxin formulations, supported by strategic partnerships and licensing agreements.

What role does technology play in Revance's strategy?

Technology is pivotal for Revance, as its proprietary peptide delivery system differentiates its products by enabling precise administration methods that optimize both patient outcomes and treatment efficacy.

How does Revance maintain trust and expertise in the industry?

Revance demonstrates its commitment to quality through rigorous clinical trials, robust research and development processes, and strategic partnerships that reinforce its authoritativeness and reliability.

Can you explain the significance of the TransMTS® delivery system?

The TransMTS® technology enables the delivery of botulinum toxin in both a non-invasive topical form and a traditional injectable form, allowing for targeted treatment at the injection site and potentially enhancing the duration of therapeutic effects.

What should investors know about Revance's strategic positioning?

Investors should note that Revance is strategically positioned in a high-growth segment of the biotechnology and aesthetics sectors, offering innovative product formulations and maintaining robust clinical pipelines.